Trial
NCT05255666
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
Merck Sharp & Dohme LLC; Ipsen
Condition
Triple Negative Breast Cancer
Intervention
Pembrolizumab
Why stopped
No drug
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-11